News & Insights

The Indermitte Presentation: When the authorities aren't familiar with GENEROUS

KP2 Confidentiality: Protection Against MFN Is Not Effective

Prevalence criterion: Discretion rather than methodology

List of Specialties: Is There Still Hope for Legal Protection?

MFN Effect: Launches in the GENEROUS basket plummet

MFN pressure on Europe and Switzerland

Industry is stepping up the pressure - Stalemate at the FOPH

"Day 0" in the specialty list: Faster access with 24-month risk

APV 2.0 in the KP2 consultation process: More net focus, more discretion, more disputes in the proceedings

Modernization of SL pricing: Why the new benefit/evidence model increases the burden of negotiation

Cost-consequence models in the specialty drug list: Where the greatest implementation risks lie for pharmaceutical companies

KP2 consultation: “Net firewall” instead of MFN protection

Stop rules as enforcement levers

TrumpRx live: Discount channel as MFN component

Working group "Life Sciences Location" as a signal to MFN

Novartis: MFN changes launch order

US wants to enshrine MFN in law

AbbVie MFN deal: lots of noise, little substance

J&J MFN deal: Switzerland as price anchor

Mounjaro: Access yes, but with limitations

Switzerland as a price anchor in GENEROUS

BAG Circular 2026

Significant price reductions following 3-year review

BAG focus page on GENEROUS

High-priced immunology and high-volume generics on the specialty list

US pricing model: Switzerland as reference country

Gaps in the provision of new therapies

BAG sets limits for 40% deductible

Pricing models and credit approvals on the rise

Time caps spread, cost approval specified.

No TQV possible? - SNB allows APV-only, stops price reduction.

Stricter limits - FOPH sends a clear price signal

Gregori Werder writes an expert opinion on the implementation of the Health Professions Act

Commentary on the Federal Supreme Court's leading ruling on the free choice of doctor

Werder Viganò advises and represents affected investors against Wendelspiess Partners AG

The first draft of the practical guidelines of the EU AI Regulation is available

Werder Viganò is featured in the new Leaders League copyright ranking.

In-home care is to be remunerated according to the Spitex tariff.

Presentation by Gregori Werder on the topic of "Employers' rights to information in the event of incapacity for work".